Abstract
We have not added the abstract for this paper yet. The publisher's page has the full record.
Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis
Alzheimer's Research & Therapy · Vol. 7 Published January 1, 2015
More on these topics
Browse all publications →-
2018 · Neurology
Memantine ER and Donepezil Treatment Maintains Cognitive Improvements Versus Donepezil Monotherapy: Post Hoc Analyses From a Placebo-controlled Study in Patients with Moderate-to-Severe Alzheimer's Disease (P6. 176)
-
2017 · Alzheimer's & Dementia
[P4-573]: A PHASE 2 MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF EDONERPIC (T-817) IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE
-
2017 · Neurology
Response Across Multiple Outcome Measures in a Randomized Trial of Extended-release Memantine (28 mg, once daily) in Patients with Moderate to Severe Alzheimer's Disease Receiving Donepezil (P3. 086)
-
2017 · Alzheimer's & Dementia
[04-03-01]: MAINTENANCE OF COGNITIVE IMPROVEMENT TREATMENT RESPONSE WITH MEMANTINE AND DONEPEZIL: POST HOC ANALYSES FROM A PLACEBO-CONTROLLED STUDY IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER'S DISEASE